Cytotoxics and High Potency Manufacturing
- All
- APIs
- Aseptic Processing
- cGMP Manufacture
- Cleaning Validation
- Clinical Trial Materials
- Cytotoxics and High Potency Manufacturing
- Excipients
- Extractables and Leachables
- Facilities
- Fill/Finish
- Lyophilization
- Parenterals
- Process Development
- Process Validation
- Risk Management
- Scale-up/Technology Transfer
- Solid Dosage/Creams/Ointments
-
Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News | Solid Dosage/Creams/Ointments
Bora Pharmaceuticals to Expand Operations
Will invest $10 million in oral solid dose capabilities across facilities in Taiwan and Canada.04.21.22
-
Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Aenova Invests in New Building for the Production of Highly Potent Drugs
Increases production capacity to meet market demand with an investment of roughly €10 million at Regensburg site.04.11.22
-
APIs | Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
AGC to Expand Synthetic Pharmaceutical Production in Spain
$100 million investment will increase current production capacity by 30% and include facilities for HPAPIs.04.08.22
-
cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Fill/Finish | Parenterals | Vials
Manufacturing Equipment Evolves to Address Today's Production Needs
Dr. Andreas Mattern, VP Strategy & Global Product Management Pharma at Syntegon discusses some of the latest advances in manufacturing equipment.Online Exclusives Kristin Brooks, Managing Editor, Contract Pharma 04.07.22
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Lonza Expands API Development and Manufacturing Laboratories in Nansha, China
Will provide additional early-phase highly-potent API manufacturing capabilities.03.08.22
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Olon Expands High Containment API Operations
The CDMO plans to invest €27 million over the next two years including a newly commissioned production line.02.09.22
-
Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Drug Development | Formulation Development | Industry News
Adare Pharma Solutions Acquires Frontida BioPharm
Expands CDMO offerings to include new capabilities such as high potency compound handling and packaging services.12.01.21
-
APIs | Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Excipients | Industry News
CordenPharma Invests €9.7M in New CTD Facility at Plankstadt CoE
To design and install GMP Clinical Trial Development facility for the manufacture of oral solid dosage drug products.11.30.21
-
Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Micro-Sphere Expands Capabilities with $3.5M Investment
Swiss CDMO invests in powder containment and extends spray drying capabilities.11.08.21
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing
FLAMMA USA Completes Commissioning of HPAPI Suite
Flamma has undergone an extensive qualification of the HPAPI suite over the past six months in order to bring this offering to the marketplace.11.01.21
-
APIs | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
MilliporeSigma Launches New Tech and Expanded ADC Capacity
ChetoSensar technology improves ADC solubility, to enhance ADC capabilities at clinical manufacturing facility in St. Louis, MO.10.28.21
-
Breaking News | Cytotoxics and High Potency Manufacturing | Industry News
Ardena Acquires Idifarma from Suanfarma and Sodena
Adds spray drying technology and high potency capabilities.09.02.21
-
Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
Lonza Extends Large-Scale MAb Commercial Supply Pact
To provide commercial-scale manufacture of monoclonal antibodies under a long-term agreement at Visp site.07.19.21
-
Breaking News | Cytotoxics and High Potency Manufacturing | Industry News | Solid Dosage/Creams/Ointments
Idifarma Launches Accelerated Pathway for Complex Drugs
‘Simply to Clinic’ leverages expertise in oral standard and highly potent drugs to take projects from pre-formulation to clinical trials.07.14.21
-
APIs | Cytotoxics and High Potency Manufacturing | Drug Development
Leverage the Benefits of Biocatalysis with the Right API CDMO
A powerful tool for organic synthesis, enzymatic chemistry has become an established methodology for manufacturing APIs.
-
Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Cytotoxics and High Potency Manufacturing | Industry News
Novasep, Exelixis Ink ADC Manufacturing Agreement
Covers the cGMP clinical manufacturing of a next-generation ADC drug candidate.07.06.21
-
APIs | Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
Lonza Expands API Development, Mfg. Facility in China
20M CHF investment will include three 1,000L GMP trains and new development and GMP labs with HPAPI capabilities.06.28.21
-
APIs | Cytotoxics and High Potency Manufacturing | Formulation Development | Process Development
Solubility Enhancement of Hydrophobic Drugs and APIs Using Hot Melt Extrusion
Efficient processing and production technology for solid molecular dispersion, HME can provide sustained, modified and targeted drug delivery.Ameya Deshpande, Formulation Scientist, Avomeen 05.25.21
-
Bio News | Breaking News | cGMP Manufacture | Collaborations & Alliances | Cytotoxics and High Potency Manufacturing | Industry News
Avid Bioservices to Manufacture Zynlonta for ADC Therapeutics
Zynlonta is an antibody drug conjugate approved for cancer treatment.Charles Sternberg, Assistant Editor 05.25.21
-
Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Novasep Expands HPAPI Manufacturing Capacity
Responds to increasing customer demand for manufacturing services for antibody drug conjugates.Tim Wright, Editor, Contract Pharma 05.13.21
